Location Directory

Clinical trials in Phoenix, Arizona

This page shows live ClinicalTrials.gov search results for Phoenix, Arizona, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 3:35 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

8161

Shown on this page

Current sort

Institutions in Phoenix

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Mayo Clinic

Live official records

Open in full search

Conditions: Pancreatic Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Endoscopic Ultrasound, Endoscopic Ultrasound-Guided Fine-Needle Aspiration, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Surgical Procedure; Procedure · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 50 Years to 75 Years
Enrollment: 770 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2034
U.S. locations: 413
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 294 more

Conditions: Fibromyalgia
Interventions: AXS-14 (Esreboxetine), Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 53
States / cities: Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 46 more

Conditions: Psoriasis, Overweight or Obesity
Interventions: Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 39
States / cities: Phoenix, Arizona • Fountain Valley, California • Fremont, California + 35 more

Conditions: Parkinson's Disease
Interventions: Standard of Care; Other
Lead sponsor: Bayer; Industry
Eligibility: 45 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 27
States / cities: Phoenix, Arizona • Tucson, Arizona • Fountain Valley, California + 23 more

Conditions: Major Depressive Disorder
Interventions: BMS-986511, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 21
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 18 more

Conditions: Breast Carcinoma
Interventions: Electronic Health Record Review, Health Promotion and Education, Health Telemonitoring, Patient Navigation, Survey Administration, Text Message-Based Navigation Intervention; Other · Procedure · Behavioral
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 499
States / cities: Fairbanks, Alaska • Kingman, Arizona • Phoenix, Arizona + 338 more

Conditions: Chronic Pain, Low Back Pain
Interventions: LY4065967, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Palm Springs, California + 31 more

Conditions: Hematologic Malignancies
Interventions: SLS009, venetoclax, azacitidine; Drug
Lead sponsor: Sellas Life Sciences Group; Industry
Eligibility: 12 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 16 more

Conditions: Wet Age Related Macular Degeneration, wAMD
Interventions: EYP-1901, Aflibercept (2.0 mg); Drug
Lead sponsor: EyePoint Pharmaceuticals, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 78
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 69 more

Conditions: Dementia With Lewy Bodies
Interventions: Neflamapimod, Placebo; Drug
Lead sponsor: EIP Pharma Inc; Industry
Eligibility: 55 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 29
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 26 more

Conditions: Age-Related Macular Degeneration
Interventions: ASP7317, tacrolimus, trimethoprim-sulfamethoxazole, Acyclovir, Nystatin; Drug
Lead sponsor: Astellas Institute for Regenerative Medicine; Industry
Eligibility: 50 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 20
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more

Conditions: Muscular Atrophy, Spinal
Interventions: Nusinersen, ThecaFlex DRx System; Drug · Device
Lead sponsor: Biogen; Industry
Eligibility: 3 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 12
States / cities: Phoenix, Arizona • Orange, California • Palo Alto, California + 9 more

Clinical trials in Phoenix, Arizona

Filter and sort this location

Institutions in Phoenix

Live official records

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications

A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder

Mobile Health for Adherence in Breast Cancer Patients

A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back Pain

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)